Format

Send to

Choose Destination
Cancer Discov. 2017 May;7(5):522-538. doi: 10.1158/2159-8290.CD-16-0932. Epub 2017 Feb 15.

Gut Microbiota Promotes Obesity-Associated Liver Cancer through PGE2-Mediated Suppression of Antitumor Immunity.

Author information

1
Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, Chiba, Japan.
2
Division of Cancer Biology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
3
LSI Medience Corporation, Tokyo, Japan.
4
Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
5
Department of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
6
Department of Pharmaceutical Biochemistry, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
7
Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.
8
CREST, Japan Science and Technology Agency (JST), Saitama, Japan.
9
Department of Pharmacology, Graduate School of Medicine, Kyoto University, Yoshida-Konoé-cho, Kyoto, Japan.
10
Center for Innovation in Immunoregulation Technology and Therapeutics, Kyoto University Graduate School of Medicine, Konoe-cho Yoshida, Kyoto, Japan.
11
Medical Innovation Center, Kyoto University Graduate School of Medicine, Kyoto, Japan.
12
AMED-CREST, AMED, Japan Agency for Medical Research and Development, Tokyo, Japan.
13
Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
14
Laboratory for Metabolomics, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.
15
Graduate School of Medical Life Science, Yokohama City University, Kanagawa, Japan.
16
PRESTO, Japan Science and Technology Agency, Kawaguchi, Saitama, Japan.
17
Division of Physiological Chemistry and Metabolism, Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan.
18
Department of Molecular Microbiology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
19
Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, Chiba, Japan. ohtani.naoko@med.osaka-cu.ac.jp.

Abstract

Obesity increases the risk of cancers, including hepatocellular carcinomas (HCC). However, the precise molecular mechanisms through which obesity promotes HCC development are still unclear. Recent studies have shown that gut microbiota may influence liver diseases by transferring its metabolites and components. Here, we show that the hepatic translocation of obesity-induced lipoteichoic acid (LTA), a Gram-positive gut microbial component, promotes HCC development by creating a tumor-promoting microenvironment. LTA enhances the senescence-associated secretory phenotype (SASP) of hepatic stellate cells (HSC) collaboratively with an obesity-induced gut microbial metabolite, deoxycholic acid, to upregulate the expression of SASP factors and COX2 through Toll-like receptor 2. Interestingly, COX2-mediated prostaglandin E2 (PGE2) production suppresses the antitumor immunity through a PTGER4 receptor, thereby contributing to HCC progression. Moreover, COX2 overexpression and excess PGE2 production were detected in HSCs in human HCCs with noncirrhotic, nonalcoholic steatohepatitis (NASH), indicating that a similar mechanism could function in humans.Significance: We showed the importance of the gut-liver axis in obesity-associated HCC. The gut microbiota-driven COX2 pathway produced the lipid mediator PGE2 in senescent HSCs in the tumor microenvironment, which plays a pivotal role in suppressing antitumor immunity, suggesting that PGE2 and its receptor may be novel therapeutic targets for noncirrhotic NASH-associated HCC. Cancer Discov; 7(5); 522-38. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 443.

PMID:
28202625
DOI:
10.1158/2159-8290.CD-16-0932
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center